Title |
Immunogenic properties and antigenic similarity of virus-like particles derived from human polyomaviruses / |
Authors |
Lučiūnaitė, Asta ; Dalgėdienė, Indrė ; Vasiliūnaitė, Emilija ; Norkienė, Milda ; Kučinskaitė-Kodzė, Indrė ; Žvirblienė, Aurelija ; Gedvilaitė, Alma |
DOI |
10.3390/ijms24054907 |
Full Text |
|
Is Part of |
International journal of molecular sciences.. Basel : MDPI. 2023, vol. 24, iss. 5, art. no. 4907, p. [1-18].. ISSN 1661-6596. eISSN 1422-0067 |
Keywords [eng] |
antibodies ; immune response ; macrophages ; polyomavirus ; viral antigens |
Abstract [eng] |
Polyomaviruses (PyVs) are highly prevalent in humans and animals. PyVs cause mild illness, however, they can also elicit severe diseases. Some PyVs are potentially zoonotic, such as simian virus 40 (SV40). However, data are still lacking about their biology, infectivity, and host interaction with different PyVs. We investigated the immunogenic properties of virus-like particles (VLPs) derived from viral protein 1 (VP1) of human PyVs. We immunised mice with recombinant HPyV VP1 VLPs mimicking the structure of viruses and compared their immunogenicity and cross-reactivity of antisera using a broad spectrum of VP1 VLPs derived from the PyVs of humans and animals. We demonstrated a strong immunogenicity of studied VLPs and a high degree of antigenic similarity between VP1 VLPs of different PyVs. PyV-specific monoclonal antibodies were generated and applied for investigation of VLPs phagocytosis. This study demonstrated that HPyV VLPs are highly immunogenic and interact with phagocytes. Data on the cross-reactivity of VP1 VLP-specific antisera revealed antigenic similarities among VP1 VLPs of particular human and animal PyVs and suggested possible cross-immunity. As the VP1 capsid protein is the major viral antigen involved in virus-host interaction, an approach based on the use of recombinant VLPs is relevant for studying PyV biology regarding PyV interaction with the host immune system. |
Published |
Basel : MDPI |
Type |
Journal article |
Language |
English |
Publication date |
2023 |
CC license |
|